InvestorsHub Logo
Followers 12
Posts 1139
Boards Moderated 0
Alias Born 02/13/2018

Re: misiu143 post# 178985

Saturday, 08/14/2021 1:56:53 PM

Saturday, August 14, 2021 1:56:53 PM

Post# of 233253
From a patient care perspective I agree with you 100%

From a trial design perspective where the objective is hitting on primary endpoints, I’m not concerned at all. I think having a secondary endpoint looking at early readmission rates would help provide guidance on continuing therapy post discharge. Honestly, at this moment in time all I care about is getting approval and getting access to patients before the next variant spreads
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News